Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 13/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800175 | 0.98 | P2RY6 (0.58) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL2176031 | 0.90 | P2RY6 (0.47) | POLA1P2RY2P2RY4P2RY6 | |
| Triphosphate SCHEMBL28074755 | 0.89 | P2RY6 (0.49) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL31398378 | 0.87 | POLA1 (0.57) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL2011098 | 0.87 | P2RY2 (0.62) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL30423444 | 0.87 | P2RY2 (0.60) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL30367562 | 0.86 | P2RY2 (0.57) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL34463723 | 0.86 | P2RY14 (0.45) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL31381447 | 0.85 | P2RY14 (0.56) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL18486642 | 0.85 | P2RY6 (0.59) | POLA1P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080150-A | Mutant of L protein of rift valley fever virus and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260130950-A1 | METHODS OF DELIVERY OF ISLET CELLS AND RELATED METHODS | SANA BIOTECHNOLOGY INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4716541-A2 | METHODS OF DELIVERY OF ISLET CELLS AND RELATED METHODS | Sana Biotechnology, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4704867-A1 | METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS | Sana Biotechnology, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260048086-A1 | METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS | SANA BIOTECHNOLOGY INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260028622-A1 | RNA NANOSTRUCTURES WITH BASE MODIFICATIONS FOR REDUCING INNATE IMMUNOGENICITY | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250360157-A1 | CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF | Wake Forest Univesity Health Sciences (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4642443-A1 | TREATMENT OF CANCER WITH A COMBINATION OF AN ANTIBODY THAT BINDS EGFR AND CYTOTOXIC DRUGS | Merus N.V. (NL) | 2025-11-05 | — | — | EP | disclosed |
| US-20250333476-A1 | ENGINEERED CD47 PROTEINS AND USES THEREOF | SANA BIOTECHNOLOGY INC (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046746-A2 | MEDICAL IMPLANTS AND FIBROSIS-INDUCING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005044142-A2 | INTRAVASCULAR DEVICES AND FIBROSIS-INDUCING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20040265368-A1 | Combination compositions of camptothecins and fluoropyrimidines | CELATOR PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004087115-A2 | COMBINATION COMPOSITIONS OF CAMPTOTHECINS AND FLUOROPYRIMIDINES | CELATOR PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087105-A1 | COMBINATION FORMULATIONS OF PLATINUM AGENTS AND FLUOROPYRIMIDINES | CELATOR PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-0561303-B1 | Conjugates of phenylalanine-glycine with antitumor substances | KUREHA CHEMICAL IND CO LTD (JP) | 1997-02-26 | — | — | EP | disclosed |
| US-5470960-A | Antitumor agents | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| US-5411964-A | Phenylalanine-glycine compounds having anti-tumor activity, process for preparation thereof, and pharmaceutical composition containing said compounds | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| EP-0561303-A2 | Conjugates of phenylalanine-glycine with antitumor substances | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360157-A1 | CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF | DPYD, DUT, UNG | POLA1 226/4885P2RY2 3816/4885P2RY4 3497/4885 |
| US-20260048086-A1 | METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS | CD47, IAPP, HBG1 | POLA1 4852/4885P2RY2 3422/4885P2RY4 3901/4885 |
| US-20260028622-A1 | RNA NANOSTRUCTURES WITH BASE MODIFICATIONS FOR REDUCING INNATE IMMUNOGENICITY | NSUN3, TARBP1, TRDMT1 | POLA1 354/4885P2RY2 4550/4885P2RY4 4226/4885 |
| US-20260130950-A1 | METHODS OF DELIVERY OF ISLET CELLS AND RELATED METHODS | IAPP, GLP1R, PNLIP | POLA1 4790/4885P2RY2 950/4885P2RY4 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.